Butenolide endothelin antagonists with improved aqueous solubility.
Continued development around our ETA-selective endothelin (ET) antagonist 1 (CI-1020) has led to the synthesis of analogues with improved aqueous solubility profiles. Poor solubility characteristics displayed by 1 required a complex buffered formulation in order to conduct iv studies. To overcome the use of specific iv formulations for preclinical studies on additional drug candidates, analogues with improved aqueous solubility were desired. Several analogues were synthesized with substitution patterns that allowed for the formation of either acid or base addition salts. These derivatives had dramatically improved aqueous solubility. In addition, these analogues retained equivalent or improved ETA receptor selectivity and antagonist potency, versus 1, both in vitro and in vivo. Compound 29, which contains as a substituent the sodium salt of a sulfonic acid, has an ETA IC50 = 0.38 nM, ETA selectivity of 4200-fold, and ETA functional activity of KB = 7.8, all of which are similar or superior to those of 1. Compound 29 also has vastly superior aqueous solubility and solubility duration, compared to 1. Furthermore, 29 after iv infusion displays improved activity to 1 in preventing acute hypoxia-induced pulmonary hypertension in rats with an ED50 = 0.3 microg/kg/h.
Patt
W C
WC
Department of Chemistry, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
Cheng
X M
XM
Repine
J T
JT
Lee
C
C
Reisdorph
B R
BR
Massa
M A
MA
Doherty
A M
AM
Welch
K M
KM
Bryant
J W
JW
Flynn
M A
MA
Walker
D M
DM
Schroeder
R L
RL
Haleen
S J
SJ
Keiser
J A
JA
D000818:Animals; D001557:Benzenesulfonates / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D004149:Dioxoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D065128:Endothelin Receptor Antagonists; D005263:Femoral Artery / Q000187:drug effects / Q000502:physiology; D006863:Hydrogen-Ion Concentration; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000517:prevention & control; D000860:Hypoxia / Q000150:complications; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A; D012995:Solubility; D013329:Structure-Activity Relationship
C119800:3-(5-(4-benzo(1,3)dioxol-5-yl-2-hydroxy-2-(4-methoxyphenyl)-5-oxo-2,5-dihydrofuran-3-ylmethyl)-2,3-dimethoxyphenoxy)propane-1-sulfonic acid; D001557:Benzenesulfonates; D004149:Dioxoles; D065128:Endothelin Receptor Antagonists; D044022:Receptor, Endothelin A